The Latin America, Middle East and Africa Cardiac Marker Testing Market should witness market growth of 10.6% CAGR during the forecast period (2022-2028).
Patients with chest pain and suspicion of acute coronary syndrome are diagnosed and risk-stratified using cardiac markers, and cardiac troponin (especially troponin I) is particularly helpful in the diagnosis of myocardial infection because of its higher specificity compared to certain other cardiac markers. Non-ST-segment elevation MI is now the term used to describe people with myocardial infarction symptoms and high troponin I or troponin T but no alterations in their electrocardiogram.
There are now high-sensitivity cardiac troponin assays that can measure troponin readings at significantly lower concentrations. More individuals with unstable angina will be labeled as having non-ST-elevation myocardial infarction due to the use of these high-sensitivity diagnostics. These tests may therefore identify a group of individuals who are at high risk, which could then receive more suitable treatment and have better results.
One aspect of the increase in illnesses is the region's population's aging. The country of South Africa has an estimated population of 56.5 million people, according to Statistics South Africa's most recent mid-year population predictions. Furthermore, South Africa's elderly population - defined as those 60 and older - is increasing and reached 8.1% in 2017. In South Africa, there are 4.6 million people over the age of 60.
The Brazil market dominated the LAMEA Cardiac Marker Testing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $127.1 million by 2028. The Argentina market is experiencing a CAGR of 11.2% during (2022-2028). Additionally, The UAE market would display a CAGR of 10.3% during (2022-2028).
Based on Disease, the market is segmented into Myocardial Infarction, Congestive Heart Failure, Atherosclerosis, Acute Coronary Syndrome and Ischemia. Based on End-user, the market is segmented into Laboratory Testing Facilities, Point-of-Care Testing Facilities and Academic Institutions. Based on Product, the market is segmented into Reagents & Kits and Instruments. Based on Biomarker Type, the market is segmented into Troponin I & T, Creatine kinase-MB(CK-MB), Natriuretic peptide (Bnp Or Nt-Probnp), Myoglobin, High-sensitivity C-reactive protein(hs-CRP) and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG (Siemens AG), PerkinElmer, Inc., BioMérieux S.A., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., and DiaSorin S.p.A.
Patients with chest pain and suspicion of acute coronary syndrome are diagnosed and risk-stratified using cardiac markers, and cardiac troponin (especially troponin I) is particularly helpful in the diagnosis of myocardial infection because of its higher specificity compared to certain other cardiac markers. Non-ST-segment elevation MI is now the term used to describe people with myocardial infarction symptoms and high troponin I or troponin T but no alterations in their electrocardiogram.
There are now high-sensitivity cardiac troponin assays that can measure troponin readings at significantly lower concentrations. More individuals with unstable angina will be labeled as having non-ST-elevation myocardial infarction due to the use of these high-sensitivity diagnostics. These tests may therefore identify a group of individuals who are at high risk, which could then receive more suitable treatment and have better results.
One aspect of the increase in illnesses is the region's population's aging. The country of South Africa has an estimated population of 56.5 million people, according to Statistics South Africa's most recent mid-year population predictions. Furthermore, South Africa's elderly population - defined as those 60 and older - is increasing and reached 8.1% in 2017. In South Africa, there are 4.6 million people over the age of 60.
The Brazil market dominated the LAMEA Cardiac Marker Testing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $127.1 million by 2028. The Argentina market is experiencing a CAGR of 11.2% during (2022-2028). Additionally, The UAE market would display a CAGR of 10.3% during (2022-2028).
Based on Disease, the market is segmented into Myocardial Infarction, Congestive Heart Failure, Atherosclerosis, Acute Coronary Syndrome and Ischemia. Based on End-user, the market is segmented into Laboratory Testing Facilities, Point-of-Care Testing Facilities and Academic Institutions. Based on Product, the market is segmented into Reagents & Kits and Instruments. Based on Biomarker Type, the market is segmented into Troponin I & T, Creatine kinase-MB(CK-MB), Natriuretic peptide (Bnp Or Nt-Probnp), Myoglobin, High-sensitivity C-reactive protein(hs-CRP) and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG (Siemens AG), PerkinElmer, Inc., BioMérieux S.A., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., and DiaSorin S.p.A.
Scope of the Study
By Disease
- Myocardial Infarction
- Congestive Heart Failure
- Atherosclerosis
- Acute Coronary Syndrome
- Ischemia
By End-user
- Laboratory Testing Facilities
- Point-of-Care Testing Facilities
- Academic Institutions
By Product
- Reagents & Kits
- Instruments
By Biomarker Type
- Troponin I & T
- Creatine kinase-MB(CK-MB)
- Natriuretic peptide (Bnp Or Nt-Probnp)
- Myoglobin
- High-sensitivity C-reactive protein(hs-CRP)
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Danaher Corporation
- Siemens Healthineers AG (Siemens AG)
- PerkinElmer, Inc.
- BioMérieux S.A.
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific, Inc.
- DiaSorin S.p.A.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. LAMEA Cardiac Marker Testing Market by Disease
Chapter 5. LAMEA Cardiac Marker Testing Market by End-user
Chapter 6. LAMEA Cardiac Marker Testing Market by Product
Chapter 7. LAMEA Cardiac Marker Testing Market by Biomarker Type
Chapter 8. LAMEA Cardiac Marker Testing Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Danaher Corporation
- Siemens Healthineers AG (Siemens AG)
- PerkinElmer, Inc.
- BioMérieux S.A.
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific, Inc.
- DiaSorin S.p.A.
Methodology
LOADING...
